Compare ARK Space & Defense Innovation ETF (ARKX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Zoetis Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $34.69, while Zoetis Inc trades at $73.74 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while ARK Space & Defense Innovation ETF pays none, and ARK Space & Defense Innovation ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| ARKX | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $156.76 |
52-Week Low | $25.46 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKX trades at $34.69, up 0.81% with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on space and defense innovation, with key holdings like SpaceX and Rocket Lab. Recent news highlights strong interest in space economy ETFs as alternatives to direct SpaceX investment, with ARKX noted for outperforming peers in one-year returns despite higher volatility.
The outlook for ARKX is positive due to growing space industry tailwinds, but risks include high expense ratios and volatility. Investment appeal lies in diversified exposure to disruptive tech, though valuation concerns for holdings like SpaceX and competitive ETF options warrant caution for risk-averse investors.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
